Your browser doesn't support javascript.
loading
Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review.
Yan, Junqiang; Liu, Anran; Huang, Jiarui; Wu, Jiannan; Shen, Ruile; Ma, Hongxia; Yang, Jianxue.
Afiliación
  • Yan J; Key Laboratory of Neuromolecular Biology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
  • Liu A; Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
  • Huang J; Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
  • Wu J; Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
  • Shen R; Key Laboratory of Neuromolecular Biology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
  • Ma H; Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
  • Yang J; Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Front Aging Neurosci ; 13: 709878, 2021.
Article en En | MEDLINE | ID: mdl-34483882
To review the therapeutic effects of drugs on REM sleep behavior disorder (RBD) in Parkinson's disease (PD) by searching the MEDLINE/PubMed, Embase, Cochrane, and CBM databases. According to the inclusion and exclusion criteria, studies were included after excluding duplicate data. We evaluated the safety and efficacy of pharmacological intervention to improve RBD in patients with Parkinson's disease (PD-RBD). This systematic review mainly describes the drugs that can be used to treat PD-RBD patients. The results have shown that melatonin can be used as the first-line drug for PD-RBD, and clonazepam provides significant improvement on PD-RBD, androtigotine can be used as an alternative drug. However, further large-scale clinical trial studies are still needed to provide the best guidelines for the pharmacological treatment of PD-RBD.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Front Aging Neurosci Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Front Aging Neurosci Año: 2021 Tipo del documento: Article País de afiliación: China